PROK
NASDAQProKidney Corp.
Price$1.67-0.08 (-4.57%)
01:30 PM07:45 PM
News · 26 weeks32+80%
2025-12-142026-06-07
Mix2190d
- SEC Filings8(38%)
- Insider8(38%)
- Other3(14%)
- Leadership2(10%)
Latest news
25 items- PRProKidney Appoints Kenneth Locke as Chief Technical OfficerWINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Kenneth Locke as Chief Technical Officer."Ken is an accomplished leader with a proven ability to scale advanced therapy platforms and execute complex manufacturing strategies," said Bruce Culleton, M.D., CEO of ProKidney. "As we approach our pivotal topline readout in Q2 2027 and advance toward commercialization, his leadership will be critical in strengthening our technical foundation and ensuring we are well-positioned for long-term success." Mr.
- INSIDERSEC Form 4 filed by Director Jimenez Santos Jose Ignacio4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Lotvin Alan4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Fox Jennifer A.4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Doyle William F4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Sinha Uma4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Legorreta Pablo G.4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Director Pereira Brian Jg4 - PROKIDNEY CORP. (0001850270) (Issuer)
- SECProKidney Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PROKIDNEY CORP. (0001850270) (Filer)
- SECProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - PROKIDNEY CORP. (0001850270) (Filer)
- SECSEC Form 10-Q filed by ProKidney Corp.10-Q - PROKIDNEY CORP. (0001850270) (Filer)
- PRProKidney Reports First Quarter 2026 Financial Results and Business HighlightsOn track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027Peer-reviewed results from the Phase 2 REGEN-007 study were published in the Clinical Journal of the American Society of Nephrology (CJASN) in January 2026Ended Q1 2026 with $224.9 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the first q
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ProKidney Corp.SCHEDULE 13D/A - PROKIDNEY CORP. (0001850270) (Subject)
- INSIDERLarge owner Control Empresarial De Capitales S.A. De C.V. converted options into 63,118,645 units of Class A Common Shares (SEC Form 4)4 - PROKIDNEY CORP. (0001850270) (Issuer)
- SECSEC Form DEFA14A filed by ProKidney Corp.DEFA14A - PROKIDNEY CORP. (0001850270) (Filer)
- SECSEC Form DEF 14A filed by ProKidney Corp.DEF 14A - PROKIDNEY CORP. (0001850270) (Filer)
- PRProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerWINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operation
- SECSEC Form S-8 filed by ProKidney Corp.S-8 - PROKIDNEY CORP. (0001850270) (Filer)
- SECProKidney Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROKIDNEY CORP. (0001850270) (Filer)
- SECSEC Form 10-K filed by ProKidney Corp.10-K - PROKIDNEY CORP. (0001850270) (Filer)
- PRProKidney Reports Full Year 2025 Financial Results and Business HighlightsOn track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("Pro
- PRChronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightThe chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor
- INSIDERSEC Form 4 filed by Chief Financial Officer Coulston James4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Chief Regulatory Officer Weber Darin J.4 - PROKIDNEY CORP. (0001850270) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Girolamo Todd C4 - PROKIDNEY CORP. (0001850270) (Issuer)
PROK FAQ
6 questionsWhere does PROK stock trade?
ProKidney Corp. (PROK) is listed on NASDAQ.What sector and industry is PROK in?
ProKidney Corp. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ProKidney Corp. go public?
ProKidney Corp. (PROK) completed its IPO in 2021.What are analysts saying about PROK?
ProKidney Corp. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-12-16.What companies are similar to PROK?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare PROK side-by-side with any of them on Quantisnow.How can I track PROK on Quantisnow?
Quantisnow aggregates ProKidney Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PROK to receive live email and push alerts on every new disclosure.